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Value of the data {#sec0001}
=================

•The data presented here were obtained in order to evaluate *FGF2* gene expression in patients with colorectal cancer. This data may be of great relevance in trying to understand how *MGP* gene expression deregulation may affect patient´s prognosis.•Beneficiaries of these data are all those who seek knowledge about the molecular mechanisms that could be underlying *MGP* deregulation in tumorigenesis.•These data report the upregulation of *FGF2* gene expression in tumor tissue and its positive correlation with *MGP* gene expression in CRC. These results could provide future insights for the search of new therapeutic targets associated with *MGP* gene expression and its deregulation in cancer.

1. Data Description {#sec0002}
===================

The fibroblast growth factor (FGF) signaling network has been implicated in several pathways, such as normal cell growth, differentiation, angiogenesis and tumor development [@bib0002]. The transcription factor FGF2 is one of the most studied in terms of its role in carcinogenesis including its role in tumor cell differentiation and proliferation [@bib0002]. Moreover, it is known that FGF2 induces transcription of the *MGP* gene [@bib0003].

In this report, we describe data regarding the expression analysis performed by qRT-PCR for *FGF2,* for both normal and tumor tissues, of 23 out of 33 CRC patients [@bib0001] whose samples were still available, and 9 samples from the control group ([Fig. 1](#fig0001){ref-type="fig"}). The data showed that the expression of *FGF2* was significantly up-regulated in CRC tissues compared to matched normal tissues (p=0.002). Our data is in accordance with what was already described in the literature regarding the increase of *FGF2* expression in various tumor tissues, such as lung [@bib0004], colorectal [@bib0005], bladder [@bib0006] and prostate [@bib0007].Fig. 1Relative *MGP* and *FGF2* gene expression in samples from patients with colon adenocarcinoma. Relative *MGP* (A) and *FGF2* (B) gene expression levels were analyzed by *q*RT-PCR in a total of 9 samples from control group and 23 samples from colorectal cancer tissue (normal and tumor mucosa). The latter showed higher mRNA levels of *MGP* and *FGF2* than non-tumor tissues (*MGP* p=0.002; *FGF2* p≤0.001). Values are presented as mean ± SD. The Mann-Whitney and Kruskal Wallis non parametric tests were performed for the statistical analysis.Fig. 1

To evaluate if there is a correlation between *FGF2* expression and the clinical-pathological features of the patients, we analyzed all the variables shown in [Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"}. No statistically significant associations were found between *FGF2* expression and the clinical and pathological features of the patients.Table 1Demographic features of colorectal patientsTable 1*MGP* (n=23)*FGF2* (n=23)CharacteristicsNumber (%)Mean value of fold change*p* valueNumber (%)Mean value of fold change*p* valueGender0.0330.439 Male14 (61)3.13514 (61)2.000 Female9 (39)6.6489 (39)1.000Age (median: 71,70 years)0.5480.776 \<728 (35)2.8988 (35)4.437 ≥7215 (65)5.36915 (65)5.640Familial Cancer History0.6710.579 Yes7 (30)3.0347 (30)3.495 No16 (70)5.15516 (70)5.977Previous Pathologies0.6911.000 Yes18 (78)3.73218 (78)5.460 No5 (22)7.3085 (22)4.363Metastasis0.1770.812 Yes6 (26)8.0826 (26)5.445 No17 (74)3.24917 (74)5.143[^1]Table 2Histopathological features of patientsTable 2*MGP* (n=23)*FGF2* (n=23)CharacteristicsNumber (%)Mean value of fold change*p* valueNumber (%)Mean value of fold change*p* valueTumor Location0.6180.493 Rectum12 (52)4.67212 (52)3.967 Rectosigmoid Junction3 (13)6.2173 (13)2.479 Ascending Colon2 (9)2.6332 (9)10.730 Sigmoid1 (4)8.0041 (4)3.653 Cecum2 (9)2.7932 (9)14.938 Hepatic Angle3 (13)3 (13)Tumor Histology0.1960.655 Well Differentiated10 (44)4.01410 (44)3.400 Moderately Differentiated9 (39)2.1649 (39)7.867 Poorly Differentiated1 (4)24.0421 (4)5.530 Mucinous1 (4)8.0041 (4)3.653Mucinous Well Differentiated2 (9)6.0282 (9)3.054Tumor Stage0.2010.336 I - II9 (39)3.1559 (39)3.017 III - IV14 (61)5.38014 (61)6.639T classification0.8150.447 pT24 (18)3.9834 (18)1.866 pT318 (78)4.76318 (78)5.918 pT41 (4)2.0551 (4)6.109N classification0.3720.592 N09 (39)3.1559 (39)3.017 N18 (35)5.6268 (35)6.717 N26 (26)5.0536 (26)6.536M classification0.2270.745 M018 (78)3.29418 (78)5.505 M15 (22)8.8845 (22)4.201Hepatic Metastasis0.2270.745 Yes5 (22)8.8845 (22)4.201 No18 (78)3.29418 (78)5.505Pulmonary Metastasis0.1580.198 Yes2 (9)14.0572 (9)8.597 No21 (91)3.60021 (91)4.900*KRAS* mutations0.7280.265 Yes8 (35)4.0228 (35)7.826 No15 (65)4.77015 (65)3.833[^2]

We then evaluated the correlation between *FGF2* and *MGP* expression. *FGF2* mRNA expression determined by qRT-PCR was well correlated (r=0.572, p=0.004) with that determined for *MGP* [@bib0001] ([Fig. 2](#fig0002){ref-type="fig"}).Fig. 2Correlation between *FGF2* and *MGP* gene expression in tumor tissue. As described in experimental design in materials and methods, the correlation between *MGP* and *FGF2* gene expression was evaluated through the SPSS software, applying the Spearman coefficient correlation test in the tumor tissue and establishing a positive and significant correlation between expression of both genes (r=0.572; p=0.004).Fig. 2

In our previously published study, we found that the two step cluster analysis of the CRC samples allowed differentiating patients with a better or worse survival outcome [@bib0001]. Subsequently, we performed a multivariate classification of two step clusters [@bib0008] to determine possible patient profiles, taking into account the characteristics of categorical and numerical variables ([Table 3](#tbl0003){ref-type="table"}). This type of analysis allows the exploitation of data taking into account each variable independently from each other\'s, to try to identify homogeneous groups depending on their characteristics. Since we did not find any correlation between the high expression of *FGF2* and the overall patient survival rate ([Fig. 3](#fig0003){ref-type="fig"}), we then evaluated the prognostic value of different variables to differentiate patients in different groups according to the influence of these factors. The variables considered were: T classification, N classification, tumor staging, gender, deceased, fold change *MGP* categorized, fold change *FGF2* categorized, fold change *MGP*, fold change *FGF2*, tumor histology, KRAS mutations, tumor location, survival rate (months), polyposis and stroke. According to this analysis, patients were divided into clusters 1 and 2. Patients in cluster 1 presented a stage N0 of lymph node metastasis (50%), the tumor was either in stage II (33.3%) or stage III (44.4%), mostly male (72.2%), with low *MGP* (72.2%) and *FGF2* (55.6%) levels of expression, with a fold change for *MGP* of 3.09 (±3.03) and for *FGF2* of 4.89 (±6.81), with a tumor histology showing either a moderately (44.4%) or well differentiated tumor (44.4%), without mutation on KRAS (61.1%), with a T3 classification (72.2%), with a mean survival time of 49.61 (±18.6) months, with the tumor mostly located in rectum (38.8%) and without the presence of polyposis (88.9) and no stroke (88.9%). Patients in cluster 2 presented a stage N1 of lymph node metastasis (60%), the tumor was either in stage III (20%) or stage IV (80%), mostly female (80%), with high *MGP* (100%) and *FGF2* (80%) levels of expression, with a fold change for *MGP* of 9.61 (±8.4) and for *FGF2* of 6.38 (±5.0), with a well differentiated tumor histology (40%), without mutation on KRAS (80%), with a T3 classification (100%), with a mean survival time of 18.00 (±8.2) months, with the tumor located in rectum (100%) and without the presence of polyposis (100%) and no stroke (100%).Table 3Multivariate analysis of predictor factorsTable 3CharacteristicsCluster 1 (n=18, %)Cluster 2 (n=5, %)*p* valueN Classification*p*=0.126[1](#tb3fn1){ref-type="table-fn"} N09 (50)0 (0) N15 (27.8)3 (60) N24 (22.2)2 (40)Tumor Staging***p*=0.05**[1](#tb3fn1){ref-type="table-fn"} Stage I3 (16.7)0 (0) Stage II6 (33.3)0 (0) Stage III8 (44.4)1 (20) Stage IV1 (5.6)4 (80)Gender***p*=0.05**[1](#tb3fn1){ref-type="table-fn"} Male13 (72.2)1 (20) Female5 (27.8)4 (80)Deceased***p*=0.05**[1](#tb3fn1){ref-type="table-fn"} No18 (100)0 (0) Yes0 (0)5 (100)Fold change *MGP* categorized***p*=0.05**[1](#tb3fn1){ref-type="table-fn"} High *MGP*5 (27.8)5 (100)Fold change *FGF2* categorized8 (44.4)4 (80)*p*=0.159[1](#tb3fn1){ref-type="table-fn"}High *FGF2*Fold Change *MGP*, mean (SD[2](#tb3fn2){ref-type="table-fn"})3.09(±3.03)9.61(±8.4)***p*=0.05**[3](#tb3fn3){ref-type="table-fn"}Fold change *FGF2*, mean (SD[2](#tb3fn2){ref-type="table-fn"})4.89(±6.81)6.38(±5.00)*p*=0.403[3](#tb3fn3){ref-type="table-fn"}*MGP* vs *FGF2*[5](#tb3fn5){ref-type="table-fn"}r=0.373;p=0.128r=-0.200; p=0.747Tumor Histology*p*=0.246[1](#tb3fn1){ref-type="table-fn"} Well differentiated8 (44.4)2 (40) Moderately differentiated8 (44.4)1 (20) Poorly Differentiated0 (0)1 (20) Mucinous1 (5.6)0 (0) Mucinous well differentiated1 (5.6)1 (20)KRAS mutations*p*=0.433[1](#tb3fn1){ref-type="table-fn"} No11 (61.1)4 (80)T classification*p*=0.412[1](#tb3fn1){ref-type="table-fn"} T10 (0)0 (0) T24 (22.2)0 (0) T313 (72.2)5 (100) T41 (5.6)0 (0)Survival Rate (Months), mean (SD[2](#tb3fn2){ref-type="table-fn"})49.61(±18.6)18.00(±8.2)***p*=0.05**[4](#tb3fn4){ref-type="table-fn"}Tumor Location*p*=0.320[1](#tb3fn1){ref-type="table-fn"} Rectum7 (38.8)5 (100) Rectosigmoid junction3 (16.7)0 (0) Ascending colon2 (11.1)0 (0) Sigmoid1 (5.6)0 (0) Cecum2 (11.1)0 (0) Hepatic angle3 (16.7)0 (0)Polyposis*p*=0.435[1](#tb3fn1){ref-type="table-fn"} No16 (88.9)5 (100)Stroke*p*=0.435[1](#tb3fn1){ref-type="table-fn"} No16 (88.9)5 (100)[^3][^4][^5][^6][^7][^8]Fig. 3Overall survival curve of patients with overexpression of *FGF2.* Patients with high *FGF2* gene expression appear to have a lower survival rate although this was not statistically significant (p=0.179). Small vertical lines indicate the censored cases referring to the number of patients that have not reached the terminal event during the data collection. *p*-value was calculated by log-rank test.Fig. 3

Moreover, we performed a Kaplan-Meier survival analysis to assess if *MGP* and *FGF2* could be in fact good prognostic factors in terms of overall survival rate for the two groups of patients found in the two-step cluster analysis. Patients in cluster 2, which presented a worst prognosis, had a higher mortality rate when compared with patients in cluster 1 (log-rank test p≤0.001) ([Fig. 4](#fig0004){ref-type="fig"}).Fig. 4Overall survival curve for patients categorized by clusters 1 and 2. Patients in Cluster 1 present a better survival rate, when compared with patients in cluster 2, who have a lower survival rate and a worse prognosis. Small vertical lines indicate the censored cases referring to the number of patients that have not reached the terminal event during data collection. *p*-value was calculated by log-rank test.Fig. 4

From the analysis it was perceived that patients in cluster 2 had a worst prognosis, in the way that all of these patients presented a small survival rate, and higher tumor stages when compared with patients in cluster 1. It\'s also worthy of note, that the variables that significantly contributed to the division of the patients were the tumor staging, the presence of high level of *MGP*, gender and the survival rate. This means that, per se, the high levels of *FGF2* alone are not sufficient for the clustering of patients, but in combination with other multiple variables can profile the patients into groups with a better or worst prognosis.

Despite the presence of some patients in cluster 1 presenting a T staging of 3 or even 4, this does not mean that these patients will actually have an associated worst prognosis. In fact, it was already shown in the literature that patients who presented a tumor stage III could have a better prognosis than those with a tumor stage II. For example, according to the American Joint Committee (AJCC) staging manual [@bib0009], when TNM staging is being evaluated, the clinicians have to take into account the tumor size (T), the number of lymph node metastasis, and the presence of metastasis. The stage is then categorized according to the combination of those three major factors, but the prognosis of the disease is reflected by its combination with other external variables that may also contribute to a worst and better prognosis. The conclusion from this analysis shows that it is the combination of the multiple variables analyzed, together with the high expression of *FGF2* in tumor tissue that can differentiate patients in two groups associated to a better or worst prognosis.

2. Experimental Design, Materials, and Methods {#sec0003}
==============================================

In this report we present briefly the materials and methods used to obtain the data here described. To see a more detailed material and methods, please refer to [@bib0001].

2.1. Clinical, demographic and pathological characteristics of patients {#sec0004}
-----------------------------------------------------------------------

Tissue samples, as well as clinical and pathological information, were obtained as described in the research article "Evaluation of MGP Gene Expression in Colorectal Cancer".

Clinical, demographic and histopathological information regarding patients is depicted in [tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"}.

2.2. qRT-PCR {#sec0005}
------------

Total RNA was extracted from fresh biopsies stored in RNALater (CRC (n=23) including normal adjacent tissue and healthy colonic tissue (n=9)). After quality and quantity measurements, cDNA synthesis was performed using 1 μg of the extracted RNA treated with RQ1 DNase (1U per μg of RNA; Promega) and M-MLV reverse transcriptase (ThermoFisher Scientific) according to manufacturer\'s instructions.

The expression of mRNA for *FGF2* was analyzed by 2^−ΔΔCt^ method and normalized with the expression of glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as reference gene. Primer sequences for *GAPDH* and *FGF2* were as follows: *GAPGH*: forward: 5'-TCAACGGATTTGGTCGTATTGGGCG-3' and reverse: 5'-CTCGCTCCTGGAAGATGGTGATGGG-3'; *FGF2*: forward: 5'-CAAAAACGGGGGCTTCTTCCTG-3' and reverse: 5'-CCATCTTCCTTCATAGCCAGGTAACG-3'.

Data were presented as the relative quantity of target mRNA normalized with *GAPDH* and relative to the mean expression of the control group. Please refer to the research article "Evaluation of MGP Gene Expression in Colorectal Cancer" for the analyses of expression of mRNA for *MGP* [@bib0001].

2.3. Statistical analysis {#sec0006}
-------------------------

Statistical analysis was performed using SPSS software program version 25. Values for gene expression are presented as mean and standard deviation (SD) and two-sided *P* value less than 0.05 was defined as statistically significant. Fold changes presented correspond to the ratio of the values from tumor mucosa *versus* normal mucosa. Comparisons between group variables and gene expression were estimated using non parametric statistical tests: Mann--Whitney U and Kruskal--Wallis.

The cutoff value to distinguish the patients with low and high *MGP* and *FGF2* levels were estimated taking into account the median value of the fold change for both *MGP* and *FGF2*.

A multivariate classification of two step clusters [@bib0008] was performed to determine possible patient profiles, taking into account the characteristics of categorical and numerical variables ([Table 3](#tbl0003){ref-type="table"}). This allowed the formation of cluster 1 (n=18) and cluster 2 (n=5). Spearman coefficients were considered to analyze the correlation between *MGP* and *FGF2* fold change values by the interest groups, namely, clusters and tissue samples. Overall survival probability for two groups of patients (clusters 1 and 2) was calculated using the Kaplan--Meier method; intergroup differences were determined using a log-rank test. Logistic regression analysis and ***χ***^2^ analysis were used to evaluate the independent influence of factors on the final prognosis.
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